Pluri Inc. (PLUR)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Mr. Yaacov Yanay
|
President, CEO & Director | 471.31k | -- | 1971 |
|
Ms. Liat Zalts
|
CFO & Treasurer | 267.09k | -- | 1984 |
|
Mr. Ori Shalem
|
Vice President of Operations & Manufacturing | -- | -- | -- |
|
Mr. Lior Raviv
|
Chief Technology Officer | -- | -- | -- |
|
Ms. Hagit Gal
|
General Counsel | -- | -- | 1973 |
|
Ms. Nofar Glaich-Dabach
|
Vice President of Human Resources | -- | -- | -- |
|
Ms. Efrat Kaduri
|
Chief Business Development Officer of Pharma | -- | -- | -- |
|
Mr. Nimrod Bar Zvi
|
Chief Commercial Officer | -- | -- | -- |
Pluri Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 92
Description
Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. The company develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and an immunotherapy platform. Its product candidates include PLX-PAD, which is composed of maternal mesenchymal stromal cells originating from the placenta for the treatment of various indications, such as acute muscle injuries following hip fracture, acute respiratory distress syndrome due to coronavirus Disease (COVID-19), peripheral artery disease, intermittent claudication, and critical limb ischemia; PLX-R18, composed of fetal MSC like cells originating from the placenta for the treatment of hematopoietic complications of the H-ARS, and is in Phase I clinical trial to treat hematopoietic cell transplantation; and allogeneic MAIT cell therapy platform. The company also offers cell manufacturing services and cell-based coffee; and develops and commercializes cultivated meat products. It operates in the field of regenerative medicine, food tech, immunotherapy, as well as contract development and manufacturing organization (CDMO) services for pharmaceutical and biotechnology companies under the PluriCDMO division, and AgTech. It has a collaboration agreement with Bar-Ilan University to advance cancer immunotherapy for solid tumors. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
